Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 11,586 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Myeloid Leukemia, Philadelphia Positive
Interventions: Asciminib Pediatric formulation group, Asciminib Adult formulation group; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • New York, New York

Conditions: Bronchiolitis Obliterans Syndrome (BOS)
Interventions: Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.; Combination Product · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Educational brochures; Behavioral
Lead sponsor: VA Midwest Health Care Network; Federal
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: educational intervention, Titrated pain management, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more

Conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia in Chronic Kidney Disease
Interventions: JTZ-951; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Lexington, Kentucky • Ann Arbor, Michigan • Omaha, Nebraska + 1 more

Conditions: Stroke, Inflammation
Interventions: Velocity based treadmill training, Duration based treadmill training; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Long COVID, Post Acute Sequelae of COVID-19
Interventions: 11C-PS13; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Pain, Post Traumatic Stress Disorder (PTSD)
Interventions: Transcranial Direct Current Stimulation (tDCS), Massed-Prolonged Exposure (PE), Sham Transcranial Direct Current Stimulation (tDCS); Device · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Charleston, South Carolina • Houston, Texas

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more

Conditions: Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum, Depression, Endogenous, Depression in Remission, Depression Chronic, Depression Moderate, Depression Severe
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Anemia of Chronic Kidney Disease
Interventions: JTZ-951, 14C-JTZ-951; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bulimia Nervosa, Anorexia Nervosa, Binge-Eating Disorder, Avoidant/Restrictive Food Intake Disorder
Interventions: ROADE Program; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 14 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Not listed
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Plaque Psoriasis, Psoriasis
Interventions: M923, Humira; Biological
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 20 more

Conditions: Kidney Failure, Chronic, Renal Dialysis
Interventions: somatropin; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Month to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more

Conditions: Kidney Failure, Chronic
Interventions: Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests; Diagnostic Test
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Pirtobrutinib, Positron Emission Tomography, Venetoclax, Echocardiography, Multigated Acquisition Scan, Biopsy; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions: topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions: Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure
Interventions: REGN5381, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions: anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Phoenix, Arizona • Duarte, California

Search by objective public record fields.

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Developing a COPD Case Finding Methodology for Primary Care

Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Feasibility of the ROADE Program

Functional Social Support in COPD Self-Management

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer